TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05876923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Undergo spirometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Undergo spirometry
Study: NCT05626023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human TH-SC01 cell injection
Description: Single injection of human TH-SC01 cell injection
Study: NCT05409326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study: NCT05876923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Undergo spirometry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Undergo spirometry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Undergo spirometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo muscular strength and functional endurance measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Undergo muscular strength and functional endurance measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Undergo muscular strength and functional endurance measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study: NCT05427695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei proBio65
Description: Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline Solution
Description: Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
Study: NCT05978934

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Lighting Condition (L1)
Description: This indoor lighting condition keeps a constant brightness and correlated color temperature.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Lighting Condition (L1)
Description: This indoor lighting condition keeps a constant brightness and correlated color temperature.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Lighting Condition (L2)
Description: This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Lighting Condition (L2)
Description: This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Lighting Condition (L3)
Description: This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
Study: NCT04705116

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: At least one dose of a COVID-19 vaccine.
Study: NCT05978934

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Lighting Condition (L3)
Description: This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
Study: NCT05134649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injection
Study: NCT05356689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical traction
Description: Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical traction
Description: Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
Study: NCT05069649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Tablet for oral use.
Study: NCT05483621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-hCG
Description: Treatment of spermatogenesis

Intervention type: DRUG
Group type: OTHER
Intervention: Beta-hCG
Description: Treatment of spermatogenesis
Study: NCT06394518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 for injection
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 for injection
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 for injection
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo for TNP-2092 active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo for TNP-2092 active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo for TNP-2092 active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo for TNP-2092 active drug
Study: NCT05400473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
Study: NCT05784337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-thos® Transcatheter Mitral Valve Replacement System
Description: Transcatheter Mitral Valve Replacement
Study: NCT05053997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAVIGATE
Description: Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
Study: NCT05015166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Internet delivered self-help program with therapist support
Description: During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
Study: NCT06408493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MYCardio-PEER
Description: MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
Study: NCT06100458

Intervention type: OTHER
Intervention: Skin and leakage protocol
Description: The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
Study: NCT05069649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT06165991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA
Study: NCT05409326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match TQH2722
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study: NCT04850599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT06396936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise program
Description: Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
Study: NCT06280209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 351
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 351
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 351
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 351
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
Study: NCT06564493

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT06127615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearFit
Description: Implantation of ClearFit Longeviti Craniectomy Cover
Study: NCT03989895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue Virus-1 #45AZ5 (PV-001-DV)
Description: Intratumoral injection of PV-001-DV
Study: NCT04383262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir Calcium
Description: A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium and 24.5 mg sodium alginate, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Alginate: 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate morning and night.
Study: NCT05893511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided gallbladder drainage
Description: Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics first
Description: Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
Study: NCT06458556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Morpheus
Description: Radiofrequency device treatment
Study: NCT04923711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise prescription
Description: Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise prescription
Description: Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold.
Study: NCT06317584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Empowerment Application for CAM Health Education
Description: Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written Paper for CAM Health Education
Description: Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
Study: NCT05016622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Description: Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
Study: NCT06446141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic technique
Description: Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic technique
Description: Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
Study: NCT05681312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic proteolytic enzyme (Tibrolin)
Description: Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg
Description: Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
Study: NCT05515744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean
Study: NCT05015166

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet delivered self-help program without therapist support
Description: During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
Study: NCT06168500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group
Description: 3.0mm diameter implant
Study: NCT05278572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)
Description: Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
Study: NCT05515744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Childbirth
Description: Induction or planned cesarean
Study: NCT06168500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group
Description: 3.0mm diameter implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: 4.0 diameter implant + guided bone regeneration